Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis

Authors Information
Article Notes and Dates
To Cite : Rezaee-Zavareh M S, Hesamizadeh K, Sharafi H, Alavian S M. Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis, Hepat Mon. 2017 ;17(6):e12324. doi: 10.5812/hepatmon.12324.
Abstract
1. Context
2. Methods
3. Results
4. Conclusions
Footnotes
References
  • 1. Hesamizadeh K, Alavian SM, Najafi Tireh Shabankareh A, Sharafi H. Molecular Tracing of Hepatitis C Virus Genotype 1 Isolates in Iran: A NS5B Phylogenetic Analysis with Systematic Review. Hepat Mon. 2016; 16(12)[DOI][PubMed]
  • 2. Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016; 16(3)[DOI][PubMed]
  • 3. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122(4): 889-96[DOI][PubMed]
  • 4. Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, Perez-del-Pulgar S, Garcia-Valdecasas JC, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol. 2009; 50(4): 719-28[DOI][PubMed]
  • 5. Guillouche P, Feray C. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011; 33(2): 163-74[DOI][PubMed]
  • 6. Dolatimehr F, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM, Behnava B, Gholami-Fesharaki M, et al. Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysis. Daru. 2017; 25(1): 11[DOI][PubMed]
  • 7. Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Ann Hepatol. 2017; 16(2): 188-97[DOI][PubMed]
  • 8. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016; 16(8)[DOI][PubMed]
  • 9. Moher D, Liberati A, Tetzlaff J, Altman DG, Prisma Group . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7)[DOI][PubMed]
  • 10. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health. 2014; 72(1): 39[DOI][PubMed]
  • 11. Curry MP, Forns X, Chung RT, Terrault NA, Brown RJ, Fenkel JM, et al. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015; 148(1): 100-107 e1[DOI][PubMed]
  • 12. Aqel BA, Pungpapong S, Leise M, Werner KT, Chervenak AE, Watt KD, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. Hepatology. 2015; 62(4): 1004-12[DOI][PubMed]
  • 13. Werner CR, Egetemeyr DP, Nadalin S, Konigsrainer A, Malek NP, Lauer UM, et al. Treatment of recurrent genotype 1 hepatitis C post-liver transplantation: single center experience with telaprevir-based triple therapy. Z Gastroenterol. 2014; 52(1): 27-34[DOI][PubMed]
  • 14. Pellicelli AM, Montalbano M, Lionetti R, Durand C, Ferenci P, D'Offizi G, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis. 2014; 46(10): 923-7[DOI][PubMed]
  • 15. Forns X, Charlton M, Denning J, McHutchison JG, Symonds WT, Brainard D, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology. 2015; 61(5): 1485-94[DOI][PubMed]
  • 16. Leroy V, Dumortier J, Coilly A, Sebagh M, Fougerou-Leurent C, Radenne S, et al. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation. Clin Gastroenterol Hepatol. 2015; 13(11): 1993-2001 e1-2[DOI][PubMed]
  • 17. Saab S, Jimenez M, Bau S, Goo T, Zhao D, Durazo F, et al. Treating fibrosing cholestatic hepatitis C with sofosbuvir and ribavirin: a matched analysis. Clin Transplant. 2015; 29(9): 813-9[DOI][PubMed]
  • 18. Patel N, Bichoupan K, Ku L, Yalamanchili R, Harty A, Gardenier D, et al. Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. World J Gastroenterol. 2016; 22(9): 2844-54[DOI][PubMed]
  • 19. Pischke S, Polywka S, Proske VM, Lang M, Jordan S, Nashan B, et al. Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting. Transpl Infect Dis. 2016; 18(1): 141-5[DOI][PubMed]
  • 20. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, Chung RT, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016; 36(6): 807-16[DOI][PubMed]
  • 21. Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, Henry TM, et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. Hepatology. 2015; 61(6): 1880-6[DOI][PubMed]
  • 22. Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, et al. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016; 22(35): 8050-9[DOI][PubMed]
  • 23. Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarebska-Michaluk D, Nazzal K, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016; 44(9): 946-56[DOI][PubMed]
  • 24. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016; 65(11): 1861-70[DOI][PubMed]
  • 25. Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, et al. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation. Liver Transpl. 2016; 22(10): 1367-78[DOI][PubMed]
  • 26. Martini S, Sacco M, Strona S, Arese D, Tandoi F, Dell Olio D, et al. Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis. Liver Int. 2017; 37(1): 62-70[DOI][PubMed]
  • 27. Terrault NA, Zeuzem S, Di Bisceglie AM, Lim JK, Pockros PJ, Frazier LM, et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology. 2016; 151(6): 1131-1140 e5[DOI][PubMed]
  • 28. Faisal N, Bilodeau M, Aljudaibi B, Hirsch G, Yoshida EM, Hussaini T, et al. Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. Transplantation. 2016; 100(5): 1059-65[DOI][PubMed]
  • 29. Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, et al. On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial. Antivir Ther. 2016; 21(6): 541-6[DOI][PubMed]
  • 30. Charlton M, Gane E, Manns MP, Brown RJ, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015; 148(1): 108-17[DOI][PubMed]
  • 31. Seifert LL, Vorona E, Bester C, Stahl M, Husing A, Beckebaum S, et al. Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation. Ann Transplant. 2015; 20: 561-8[DOI][PubMed]
  • 32. Dabbous HM, Montasser IF, Sakr MA, Refai R, Sayam M, Abdelmonem A, et al. Safety, Efficacy, and Tolerability of Sofosbuvir and Ribavirin in Management of Recurrent Hepatitis C Virus Genotype 4 After Living Donor Liver Transplant in Egypt: What Have We Learned so far? Hepat Mon. 2016; 16(5)[DOI][PubMed]
  • 33. Raschzok N, Schott E, Reutzel-Selke A, Damrah I, Gul-Klein S, Strucker B, et al. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C. Transpl Infect Dis. 2016; 18(6): 896-903[DOI][PubMed]
  • 34. Grant JL, Hawkins C, Brooks H, Palella FJ, Koppe SW, Abecassis MM, et al. Successful sofosbuvir-based therapy in HIV/hepatitis C virus coinfected liver transplant recipients with recurrent hepatitis C virus infection. AIDS. 2016; 30(1): 93-8[DOI][PubMed]
  • 35. Ikegami T, Yoshizumi T, Yoshida Y, Kurihara T, Harimoto N, Itoh S, et al. Telaprevir versus simeprevir for the treatment of recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2016; 46(3)-45[DOI][PubMed]
  • 36. Tanaka T, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Aoki T, et al. Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study. J Hepatobiliary Pancreat Sci. 2015; 22(2): 144-50[DOI][PubMed]
  • 37. Shinoda M, Ebinuma H, Itano O, Yamagishi Y, Obara H, Kitago M, et al. Simeprevir/pegylated interferon/ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2016; 46(11): 1118-28[DOI][PubMed]
  • 38. Ueda Y, Ikegami T, Soyama A, Akamatsu N, Shinoda M, Ishiyama K, et al. Simeprevir or telaprevir with peginterferon and ribavirin for recurrent hepatitis C after living-donor liver transplantation: A Japanese multicenter experience. Hepatol Res. 2016; 46(13): 1285-93[DOI][PubMed]
  • 39. Miuma S, Ichikawa T, Miyaaki H, Haraguchi M, Tamada Y, Shibata H, et al. Efficacy and Tolerability of Pegylated Interferon and Ribavirin in Combination with Simeprevir to Treat Hepatitis C Virus Infections After Living Donor Liver Transplantation. J Interferon Cytokine Res. 2016; 36(6): 358-66[DOI][PubMed]
  • 40. Saab S, Greenberg A, Li E, Bau SN, Durazo F, El-Kabany M, et al. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients. Liver Int. 2015; 35(11): 2442-7[DOI][PubMed]
  • 41. Punzalan CS, Barry C, Zacharias I, Rodrigues J, Mehta S, Bozorgzadeh A, et al. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015; 29(12): 1105-11[DOI][PubMed]
  • 42. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015; 21(6): 823-30[DOI][PubMed]
  • 43. Pillai AA, Wedd J, Norvell JP, Parekh S, Cheng N, Young N, et al. Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016; 111(2): 250-60[DOI][PubMed]
  • 44. Nair S, Satapathy SK, Gonzalez HC. Sofosbuvir and Simeprevir for Treatment of Recurrent Hepatitis C Infection After Liver Transplant. Exp Clin Transplant. 2017; 15(3): 314-9[DOI][PubMed]
  • 45. Jackson WE, Hanouneh M, Apfel T, Alkhouri N, John BV, Zervos X, et al. Sofosbuvir and simeprevir without ribavirin effectively treat hepatitis C virus genotype 1 infection after liver transplantation in a two-center experience. Clin Transplant. 2016; 30(6): 709-13[DOI][PubMed]
  • 46. Issa D, Eghtesad B, Zein NN, Yerian L, Cruise M, Alkhouri N, et al. Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Int J Organ Transplant Med. 2016; 7(1): 38-45[PubMed]
  • 47. Crittenden NE, Buchanan LA, Pinkston CM, Cave B, Barve A, Marsano L, et al. Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation. Liver Transpl. 2016; 22(5): 635-43[DOI][PubMed]
  • 48. Brown RJ, O'Leary JG, Reddy KR, Kuo A, Morelli GJ, Burton JJ, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016; 22(1): 24-33[DOI][PubMed]
  • 49. Khemichian S, Lee B, Kahn J, Noureddin M, Kim B, Harper T, et al. Sofosbuvir and Simeprevir Therapy for Recurrent Hepatitis C Infection After Liver Transplantation. Transplant Direct. 2015; 1(6)[DOI][PubMed]
  • 50. Lutchman G, Nguyen NH, Chang CY, Ahmed A, Daugherty T, Garcia G, et al. Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1. Aliment Pharmacol Ther. 2016; 44(7): 738-46[DOI][PubMed]
  • 51. Herzer K, Papadopoulos-Kohn A, Walker A, Achterfeld A, Paul A, Canbay A, et al. Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. Digestion. 2015; 91(4): 326-33[DOI][PubMed]
  • 52. Fontana RJ, Brown RJ, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Liver Transpl. 2016; 22(4): 446-58[DOI][PubMed]
  • 53. Herzer K, Welzel TM, Ferenci P, Petersen J, Gschwantler M, Cornberg M, et al. Daclatasvir in combination with sofosbuvir with or without ribavirin is safe and efficacious in liver transplant recipients with HCV recurrence: Interim results of a multicenter compassionate use program. Hepat. 2015; 62: 341A
  • 54. Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry P, Duvoux C, Di Martino V, et al. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. J Hepatol. 2016; 65(4): 711-8[DOI][PubMed]
  • 55. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493-505[DOI][PubMed]
  • 56. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RJ, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015; 149(3): 649-59[DOI][PubMed]
  • 57. Kwok RM, Ahn J, Schiano TD, Te HS, Potosky DR, Tierney A, et al. Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients. Liver Transpl. 2016; 22(11): 1536-43[DOI][PubMed]
  • 58. Elfeki MA, Abou Mrad R, Modaresi Esfeh J, Zein NN, Eghtesad B, Zervos X, et al. Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience. Transplantation. 2017; 101(5): 996-1000[DOI][PubMed]
  • 59. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16(6): 685-97[DOI][PubMed]
  • 60. Ciesek S, Proske V, Otto B, Pischke S, Costa R, Luthgehetmann M, et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis. 2016; 18(3): 326-32[DOI][PubMed]
  • 61. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown RJ, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014; 371(25): 2375-82[DOI][PubMed]
  • 62. Omichi K, Akamatsu N, Mori K, Togashi J, Arita J, Kaneko J, et al. Asunaprevir/daclatasvir and sofosbuvir/ledipasvir for recurrent hepatitis C following living donor liver transplantation. Hepatol Res. 2016; [DOI][PubMed]
  • 63. Adam R, Karam V, Delvart V, O'Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol. 2012; 57(3): 675-88[DOI][PubMed]
  • 64. Kim WR, Lake JR, Smith JM, Skeans MA, Schladt DP, Edwards EB, et al. OPTN/SRTR 2013 Annual Data Report: liver. Am J Transplant. 2015; 15 Suppl 2: 1-28[DOI][PubMed]
  • 65. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl. 2004; 10(9): 1120-30[DOI][PubMed]
  • 66. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz V, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology. 2000; 32(4 Pt 1): 852-8[DOI][PubMed]
  • 67. Thuluvath PJ, Guidinger MK, Fung JJ, Johnson LB, Rayhill SC, Pelletier SJ. Liver transplantation in the United States, 1999-2008. Am J Transplant. 2010; 10(4 Pt 2): 1003-19[DOI][PubMed]
  • 68. Li DL, Fang J, Zheng Z, Wu W, Wu Z. Successful treatment of fibrosing cholestatic hepatitis following kidney transplantation with allogeneic hematopoietic stem cell transplantation: a case report. Medicine (Baltimore). 2015; 94(5)[DOI][PubMed]
  • 69. Davies SE, Portmann BC, O'Grady JG, Aldis PM, Chaggar K, Alexander GJ, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991; 13(1): 150-7[DOI][PubMed]
  • 70. Xiao SY, Lu L, Wang HL. Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis. Int J Clin Exp Pathol. 2008; 1(5): 396-402[PubMed]
  • 71. Narang TK, Ahrens W, Russo MW. Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010; 16(11): 1228-35[DOI][PubMed]
  • 72. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014; 384(9956): 1756-65[DOI][PubMed]
  • 73. Simeprevir [package insert] 2015;
  • 74. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology. 2011; 54(6): 1956-65[DOI][PubMed]
  • 75. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; 384(9941): 403-13[DOI][PubMed]
  • 76. Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014; 20(11): 2902-12[DOI][PubMed]
  • 77. European Association for the Study of the Liver. Electronic address EEE. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017; 66(1): 153-94[DOI][PubMed]
  • 78. Alavian SM, Rezaee-Zavareh MS. Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis. Hepat Mon. 2016; 16(9)[DOI][PubMed]
  • 79. Rezaee-Zavareh MS, Hadi R, Karimi-Sari H, Hossein Khosravi M, Ajudani R, Dolatimehr F, et al. Occult HCV Infection: The Current State of Knowledge. Iran Red Crescent Med J. 2015; 17(11)[DOI][PubMed]
  • 80. Rezaee-Zavareh MS, Ramezani-Binabaj M, Moayed Alavian S. Screening for occult hepatitis C virus infection: Does it need special attention? Hepatology. 2015; 62(1): 321-2[DOI][PubMed]
  • 81. Elmasry S, Wadhwa S, Bang BR, Cook L, Chopra S, Kanel G, et al. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation. Gastroenterology. 2017; 152(3): 550-553 e8[DOI][PubMed]
  • 82. Rezaee Zavareh MS, Alavian SM. Occult Hepatitis C Infection Should Be More Noticed With New Treatment Strategies. Hepat Mon. 2015; 15(11)[DOI][PubMed]
  • 83. Karimi-Sari H, Tajik M, Bayatpoor ME, Alavian SM. Increasing the Awareness of the General Population: An Important Step in Elimination Programs of Viral Hepatitis? The American journal of gastroenterology 2017; 112(2): 393-5[DOI][PubMed]
  • 84. Greig SL. Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. Drugs. 2016; 76(16): 1567-78[DOI][PubMed]
  • 85. Coilly A, Roche B, Duclos-Vallee JC, Samuel D. Optimum timing of treatment for hepatitis C infection relative to liver transplantation. Lancet Gastroenterol Hepatol. 2016; 1(2): 165-72[DOI][PubMed]
  • 86. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017; 65(3): 804-12[DOI][PubMed]
  • 87. Alavian SM, Rezaee-Zavareh MS. The Middle East and hepatitis C virus infection: does it need special attention? Lancet Infect Dis. 2016; 16(9): 1006-7[DOI][PubMed]
  • 88. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4)[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check